Etranacogene Dezaparvovec
Etranacogene Dezaparvovec
Definition
A non-replicating, recombinant adeno-associated virus serotype 5 (AAV5) encoding a variant of human coagulation factor IX with a gain-of-function Padua mutation (R338L), under control of a liver-specific promotor 1 (LP1), that may potentially be used to treat hemophilia B (congenital factor IX deficiency; Christmas disease). Upon administration of etranacogene dezaparvovec and transduction of hepatocytes, human coagulation factor IX is produced. This replaces missing factor IX and may normalize the activated partial thromboplastin time (aPTT), increase blood clotting, and reduce and control bleeding episodes.
Also known as AMT-061, ETRANACOGENE DEZAPARVOVEC, Etranacogene Dezaparvovec-drlb, Hemgenix — per NCIT
Also identified as
- ATC B02BD16 per RXNORM
- NCIT NCIT:C171798 per NCIT
- SCTID 41574311000001102 per RXNORM
- UNII Z5XCD5Q9RL per RXNORM